demcizumab

On April 10, Oncomed Pharmaceuticals Inc (NASDAQ: OMED) announced demcizumab had missed its primary endpoint in the Phase 2 YOSEMITE trial in pancreatic cancer, while the company’s partner, Bayer, had decided not to opt-in to develop Wnt inhibitors vantictumab and ipafricept. H.C. Wainwright...

HC Wainwright has started coverage of Oncomed Pharmaceuticals Inc (NASDAQ: OMED) shares with a Buy rating. The firm sees 68 percent potential upside for the pharmaceutical company on upcoming opt-in decisions for its lead drug candidates expected from three partners: Celgene Corporation (NASDAQ:...